Neoantigen-Based Personalized Cancer Therapeutic Vaccines Report 2020: Competitive Landscape and Market Forecast to 2035 – ResearchAndMarkets.com

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Report 2020: Competitive Landscape and Market Forecast to 2035 – ResearchAndMarkets.com




Neoantigen-Based Personalized Cancer Therapeutic Vaccines Report 2020: Competitive Landscape and Market Forecast to 2035 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neoantigen-Based Personalized Cancer Therapeutic Vaccines – Competitive Landscape and Market Forecast to 2035” report has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Report Highlights

  • There are 10+ active players involved in developing therapies for Neoantigen-based Personalized Cancer therapeutic Vaccines. Launch of emerging vaccines will significantly impact the Neoantigen-based Personalized Cancer therapeutic Vaccines market.
  • Apart from the main company, several collaborators are also actively working to develop these potential and promising cancer vaccines. There are approximately 10+ companies involved in licensing agreements and collaborations for the development and commercialization of these vaccines.
  • Expected launch of 15+ potential Neoantigen-based Personalized Cancer therapeutic Vaccines will increase the market size in the coming years, assisted by an increase in diagnosed incident population of several cancer indications along with advancements in treatment options, which makes it clear that the upcoming cancer vaccine are majorly expected to boom the overall therapeutic market in the oncology sector by acting as an adjuvant therapy to the already existing Standard of care therapies (SOC).
  • The increase in market size is also expected due to the rising awareness regarding the current unmet need for adjuvant therapies, along with incremental healthcare spending across the world, which would expand the size of the market to enable the vaccine manufacturers to penetrate more into the market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Neoantigen-based Personalized Cancer therapeutic Vaccines.
  • A section comprising of vaccine types, which will include neo-antigen based mRNA vaccines, neo-antigen based Viral/Bacterial vaccines, neo-antigen based polypeptide vaccines, neo-antigen based Dendritic cell vaccines along, immunotherapy based vaccines along with allogeneic and autologous tumor cell based neo-antigen vaccines.
  • The report also provides detailed attribute analysis of individual vaccines based on several uniform parameters such safety , efficacy, tolerability, extent of T-cell responses, extent of tumor reductions, extent of recurrence reduction, median overall survival(MOS), progression free survival (PFS) grade level toxicity, company funding’s and collaborations
  • The companies, universities and associations are working together to assess challenges and seek opportunities that could influence Neoantigen-based Personalized Cancer therapeutic Vaccines R&D.
  • These Neoantigen-based Personalized Cancer therapeutic Vaccines are being developed based on novel technology platforms approaches, will help advance precision medicine using Improved high-throughput technologies, which are providing feasible tools for analyzing the mutation antigen profile, the gene signature and epigenetic modification of tumor and immune cells, as well as the magnitude, homing capacity, cytotoxic function and T cell receptor (TCR) repertoire of T lymphocytes.
  • Detailed SWOT Analysis
  • Detailed Therapeutic Assessment, which will include the assessment of vaccines by Major Key Players, by Phases, by Vaccine types, by route of administration, and target or primary indication.
  • The in-depth analysis of the pipeline assets across different stages of development, different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, expected launch dates along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Topics Covered:

1. Key Insights

2. Executive Summary of Neoantigen-based Personalized Cancer therapeutic Vaccines

3. Competitive Intelligence Analysis for Neoantigen-based Personalized Cancer therapeutic Vaccines

4. Neoantigen-based Personalized Cancer therapeutic Vaccines: Market Overview at a Glance

4.1. Neoantigen-based Personalized Cancer therapeutic Vaccines-Region Wise Total Market Share (%) Distribution by 2035

4.2. Neoantigen-based Personalized Cancer therapeutic Vaccines-Indication Wise Total Market Share (%) Distribution by 2035

5. Neoantigen-based Personalized Cancer therapeutic Vaccines

5.1. Introduction

5.1.1. Tumor neoantigens: from basic research to clinical applications

5.1.2. Historical overview in the understanding of tumor neoantigens

5.1.3. Neoantigens-directed immunoediting and immune escape

5.1.4. Overview of Preclinical and clinical neoantigen vaccine-based studies

5.1.4.1. Neoantigen-based adoptive T cell transfer

5.1.4.2. Neoantigen-based cancer vaccines

5.1.4.3. Combination of neoantigen vaccine with other therapies

5.1.4.3.1. Biomarker for immune checkpoint inhibitors

5.1.4.3.2. Resistance mechanism for immune checkpoint inhibitors

5.1.5. Identification and prediction of neoantigens

5.1.6. Principle of neoantigen vaccines

5.1.7. Clinical progress

5.1.8. Pros and Cons

6. Unmet Needs

7. Emerging Therapies

7.1. Key Cross Competition

7.2. Tedopi (OSE2101): OSE Immunotherapeutics

7.3. GRANITE (GRT-C901) + SLATE (GRT-R902): Gritstone Oncology

7.4. GEN-009 Adjuvanted Vaccine: Genocea Biosciences

7.5. TG01 Vaccine: Targovax

7.6. iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics

7.7. NEO-PV-01: Neon Therapeutics

7.7.1. Product Description

7.7.2. Other Developmental Activities

7.7.3. Clinical Development

7.7.4. Safety and Efficacy

7.7.5. Product Profile

8. Neoantigen-based Personalized Cancer therapeutic Vaccines: Seven Major Market Analysis

8.1. Key Findings

8.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size in 7MM

9. 7MM: Market Outlook

9.1. United States: Market Size

9.1.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in the United States

9.1.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in the United States

9.2. EU-5 countries: Market Size and Outlook

9.3. Japan Market Outlook

10. Attribute analysis

11. KOL Views

12. Market Drivers

13. Market Barriers

14. Future Outlook

15. Appendix

Companies Mentioned

  • OSE Immunotherapeutics
  • Gritstone Oncology
  • Genocea Biosciences
  • Targovax
  • Hangzhou Neoantigen Therapeutics
  • Neon Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/ftq7lh

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900